Feb 13, 2025 / 12:00PM GMT
Fredrik Dahl - Devyser Diagnostics AB - Interim CEO
Good day and welcome to the Devyser Q4 2024 earnings call.
I'm Fredrik Dahl, the acting CEO of Devyser, and would like to thank you everyone for joining our call today.
On the call today, we have in addition to myself, also our CFO Sabina Berlin, and our Chief Commercial Officer Theis Kipling.
Since this is my first earnings call for Devyser, I will start with a short introduction on who I am and my background. I will then review our updated strategy before handing over to Sabina for a review of our financial results in Q4 2024, and then to Theis for an update on our commercial activities.
I have been a board member of the Devyser since 2021 and is the acting CEO since January 16th. I have a PhD in molecular medicine from Uppsala University and carried out the post-doc, at Stanford in DNA technology development.
After my studies at Stanford, I worked in start-up scene in Silicon Valley in NextGen sequencing, and have co-founded both Halo genomics and Vanity diagnostics that we sold to Adulant and Perkin
Q4 2024 Devyser Diagnostics AB Earnings Call Transcript
Feb 13, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers